Cross Talk Pathways Between Coagulation and Inflammation
2016/04/28 by Jonathan H. Foley, Edward M. Conway · 27 citations
Medicine · #Blood Coagulation and Thrombosis Mechanisms #Coagulation, Bradykinin, Polyphosphates, and Angioedema #Venous Thromboembolism Diagnosis and Management
paper · doi:10.1161/circresaha.116.306853
Abstract
Anatomic pathology studies performed over 150 years ago revealed that excessive activation of coagulation occurs in the setting of inflammation. However, it has taken over a century since these seminal observations were made to delineate the molecular mechanisms by which these systems interact and the extent to which they participate in the pathogenesis of multiple diseases. There is, in fact, extensive cross talk between coagulation and inflammation, whereby activation of one system may amplify activation of the other, a situation that, if unopposed, may result in tissue damage or even multiorgan failure. Characterizing the common triggers and pathways are key for the strategic design of effective therapeutic interventions. In this review, we highlight some of the key molecular interactions, some of which are already showing promise as therapeutic targets for inflammatory and thrombotic disorders.
Cited by
- Effects of Inflammation on Hemostasis in Acutely Ill Patients with Liver Disease
- Emerging biomodels to understand the pathophysiology of sepsis and evaluate new therapeutic strategies targeting extracellular histones
- Resolution of Acute Inflammation and the Role of Resolvins in Immunity, Thrombosis, and Vascular Biology. [europepmc]
- Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. [europepmc]
- An update on factor XI structure and function. [europepmc]
- The Role of Inflammation in Venous Thromboembolism. [europepmc]
- Start a fire, kill the bug: The role of platelets in inflammation and infection. [europepmc]
- Complement in the Pathophysiology of the Antiphospholipid Syndrome. [europepmc]
- Thrombogenic Risk Induced by Intravascular Mesenchymal Stem Cell Therapy: Current Status and Future Perspectives. [europepmc]
- Critically ill COVID-19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability. [europepmc]
- The complement system in COVID-19: friend and foe? [europepmc]
- Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review. [europepmc]
- The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. [europepmc]
- COVID-19: Complement, Coagulation, and Collateral Damage. [europepmc]
- Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports. [europepmc]
- The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. [europepmc]
- A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment. [europepmc]
- Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets. [europepmc]
- Cardiovascular Manifestations of COVID-19 Infection. [europepmc]
- SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress. [europepmc]
- Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy. [europepmc]
- Inflammation, Infection and Venous Thromboembolism. [europepmc]
- Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. [europepmc]
- Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices. [europepmc]
- Antiplatelet therapy after percutaneous coronary intervention. [europepmc]
- The Crossroads of the Coagulation System and the Immune System: Interactions and Connections. [europepmc]
- Sepsis-Induced Coagulopathy: A Comprehensive Narrative Review of Pathophysiology, Clinical Presentation, Diagnosis, and Management Strategies. [europepmc]
Related